Who is sponsoring NCT02006589?

NCT02006589 is sponsored by GlaxoSmithKline.

What condition does NCT02006589 study?

NCT02006589 studies Hypertension.

What drugs are being tested in NCT02006589?

Interventions: Candesartan cilexetil (GW615775, Test formulation), Candesartan cilexetil (Reference treatment).

What is the status of NCT02006589?

NCT02006589 is currently COMPLETED.

Last reviewed 2017-05-15 · How we verify

Bioavailability Study of Candesartan Cilexetil 8mg Tablet Under Fasting Conditions

NCT02006589 PHASE1 COMPLETED

This will be an open-label, randomized, single dose, two-way crossover study. Each subject will participate in both treatment periods and will receive single oral doses of candesartan cilexetil (GW615775) and reference candesartan cilexetil (ATACAND™); the treatment periods will be separated by a washout period of at least 7 days and no greater than 14 days. This study aims to determine the relative bioavailability of an 8mg test formulation tablet of candesartan cilexetil (GW615775) compared to an 8mg reference tablet of candesartan cilexetil in healthy adult subjects. ATACAND is a registered trademark of the AstraZeneca group of companies.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE1
Status	COMPLETED
Enrolment	16
Start date	Wed Dec 11 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jan 22 2014 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Hypertension

Interventions

Candesartan cilexetil (GW615775, Test formulation)
Candesartan cilexetil (Reference treatment)

Countries

India